FibriLysins disrupt Staphylococcus aureus biofilms and abscess communities
Engineered FibriLysins dismantle fibrin-encapsulated Staphylococcus aureus communities and outperform vancomycin in a preclinical model of fracture-related infection.
Engineered FibriLysins dismantle fibrin-encapsulated Staphylococcus aureus communities and outperform vancomycin in a preclinical model of fracture-related infection.